A new survey suggests many people with ALS would value even modest slowing of ALS progression as a treatment goal.

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with no cure and limited treatment options.

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully ...

A recent large study conducted in Sweden has found that long-term exposure to elevated levels of air pollution may increase ...

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...

A look at Amyotrophic Lateral Sclerosis (ALS), focusing on motor neuron degeneration, sporadic versus familial ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

The TikTok star, 37, was officially diagnosed with the terminal neurodegenerative disease in 2022 ...

Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery. When Columbia neurologist and ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...